Literature DB >> 12084390

Effects of losartan on the blood-brain barrier permeability in long-term nitric oxide blockade-induced hypertensive rats.

Mutlu Kucuk1, Mehmet Kaya, Rivaze Kalayci, Vedat Cimen, Hasan Kudat, Nadir Arican, Imdat Elmas, Ferruh Korkut.   

Abstract

Hypertension is closely associated with vascular endothelial dysfunction. The aim of this study was to investigate the effects of Angiotensin II (ANG II) receptor antagonist losartan on the blood-brain barrier (BBB) permeability in L-NAME-induced hypertension and/or in ANG II-induced acute hypertension in normotensive and hypertensive rats. Systolic blood pressure was measured by tail cuff method before, during and following L-NAME treatment (1 g/L). Losartan (3 mg/kg) was given to the animal for five days. Acute hypertension was induced by ANG II (60 microg/kg). Arterial blood pressure was directly measured on the day of the experiment. BBB disruption was quantified according to the extravasation of the albumin-bound Evans blue dye. Losartan significantly reduced the mean arterial blood pressure from 169 +/- 3.9 mmHg to 82 +/- 2.9 mmHg in L-NAME and from 171 +/- 2.9 mmHg to 84 +/- 2.9 in L-NAME plus losartan plus ANG II groups (p < 0.05). The content of Evans blue dye in the cerebral cortex significantly increased in L-NAME (p < 0.01). Moreover, the content of Evans blue dye markedly increased in the cerebellum (p < 0.001) and slightly increased in diencephalon region (p < 0.05) in L-NAME plus ANG II. Losartan reduced the increased BBB permeability to Evans blue dye in L-NAME (p < 0.01) and L-NAME plus ANG II (p < 0.001). These results indicate that L-NAME and L-NAME plus ANG II both lead to an increase in microvascular Evans blue dye efflux to brain, and losartan treatment attenuates this protein-bound dye transport into brain tissue presumably due to its protective effect on endothelial cells of brain vessels.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12084390     DOI: 10.1016/s0024-3205(02)01772-1

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  12 in total

1.  Losartan prevents acquired epilepsy via TGF-β signaling suppression.

Authors:  Guy Bar-Klein; Luisa P Cacheaux; Lyn Kamintsky; Ofer Prager; Itai Weissberg; Karl Schoknecht; Paul Cheng; Soo Young Kim; Lydia Wood; Uwe Heinemann; Daniela Kaufer; Alon Friedman
Journal:  Ann Neurol       Date:  2014-05-28       Impact factor: 10.422

2.  Sodium nitroprusside is effective in preventing and/or reversing the development of schizophrenia-related behaviors in an animal model: The SHR strain.

Authors:  Mariana C Diana; Fernanda F Peres; Veronica Justi; Rodrigo A Bressan; Acioly L T Lacerda; José Alexandre Crippa; Jaime E C Hallak; Vanesssa Costhek Abilio
Journal:  CNS Neurosci Ther       Date:  2018-04-14       Impact factor: 5.243

Review 3.  Effects of angiotensin-II on brain endothelial cell permeability via PPARalpha regulation of para- and trans-cellular pathways.

Authors:  Shuzhen Guo; Angel T Som; Ken Arai; Eng H Lo
Journal:  Brain Res       Date:  2019-07-26       Impact factor: 3.252

4.  Long-Term Treatment with Losartan Attenuates Seizure Activity and Neuronal Damage Without Affecting Behavioral Changes in a Model of Co-morbid Hypertension and Epilepsy.

Authors:  Jana D Tchekalarova; Natasha Ivanova; Dimitrina Atanasova; Daniela M Pechlivanova; Nikolai Lazarov; Lidia Kortenska; Rumiana Mitreva; Valentin Lozanov; Alexander Stoynev
Journal:  Cell Mol Neurobiol       Date:  2015-10-13       Impact factor: 5.046

5.  An In Vivo Assessment of Blood-Brain Barrier Disruption in a Rat Model of Ischemic Stroke.

Authors:  Hamdollah Panahpour; Mehdi Farhoudi; Yadollah Omidi; Javad Mahmoudi
Journal:  J Vis Exp       Date:  2018-03-11       Impact factor: 1.355

6.  Losartan improved respiratory function and coenzyme Q content in brain mitochondria of young spontaneously hypertensive rats.

Authors:  Z Sumbalová; J Kucharská; F Kristek
Journal:  Cell Mol Neurobiol       Date:  2010-02-10       Impact factor: 5.046

7.  PPAR-gamma agonist rosiglitazone reverses increased cerebral venous hydraulic conductivity during hypertension.

Authors:  Tim J M Roberts; Abbie C Chapman; Marilyn J Cipolla
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-08-07       Impact factor: 4.733

Review 8.  The Potential Therapeutic Capacity of Inhibiting the Brain Renin-Angiotensin System in the Treatment of Co-Morbid Conditions in Epilepsy.

Authors:  Natasha Ivanova; Jana Tchekalarova
Journal:  CNS Drugs       Date:  2019-11       Impact factor: 5.749

Review 9.  Linking chronic kidney disease and Parkinson's disease: a literature review.

Authors:  Jesús D Meléndez-Flores; Ingrid Estrada-Bellmann
Journal:  Metab Brain Dis       Date:  2020-09-29       Impact factor: 3.584

10.  Candesartan attenuates ischemic brain edema and protects the blood-brain barrier integrity from ischemia/reperfusion injury in rats.

Authors:  Hamdollah Panahpour; Ali Akbar Nekooeian; Gholam Abbas Dehghani
Journal:  Iran Biomed J       Date:  2014
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.